94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Takashi Shimizu1,2
Eisuke Inoue3
Ryotaro Ohkuma1,4
Shinichi Kobayashi2
Takuya Tsunoda4
Satoshi Wada1,2,4,5,6*- 1Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan
- 2Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan
- 3Showa University Research Administration Center, Showa University, Tokyo, Japan
- 4Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan
- 5Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan
- 6Pharmacological Research Center, Showa University, Tokyo, Japan
A Corrigendum on
Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis
by Shimizu T, Inoue E, Ohkuma R, Kobayashi S, Tsunoda T and Wada S (2023) Front. Immunol. 14:1308381. doi: 10.3389/fimmu.2023.1308381
In the published article, there was an error in the legend for Figure 2 and Figure 3 as published. Figure 2B and Figure 3B; Hazard ratios of overall death, and Figure 3 legend; B; disease progression. The corrected legend appears below.
FIGURE 2
Figure 2 Forest plots representing hazard ratios of death (A; overall death, B; disease progression) for sPD-L1 fold changes in each trial.
FIGURE 3
Figure 3 Forest plots representing hazard ratios of death (A; overall death, B; disease progression) for sPD-L1 changes by subgroup.
Figure 2B and Figure 3B; Hazard ratios of disease progression, and Figure 3 legend; B; disease progression.
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: soluble PD-L1, advanced non-small cell lung cancer, PD-1 inhibitors, individual patient data meta-analysis, biomarker
Citation: Shimizu T, Inoue E, Ohkuma R, Kobayashi S, Tsunoda T and Wada S (2023) Corrigendum: Soluble PD−L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis. Front. Immunol. 14:1345513. doi: 10.3389/fimmu.2023.1345513
Received: 27 November 2023; Accepted: 29 November 2023;
Published: 05 December 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Shimizu, Inoue, Ohkuma, Kobayashi, Tsunoda and Wada. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Satoshi Wada, c3Qtd2FkYUBtZWQuc2hvd2EtdS5hYy5qcA==